Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase (TYR) plays a vital role in melanin biosynthesis and is widely regarded as a relatively specific marker for melanocytic lesions which involve vitiligo, malignant cutaneous melanoma, Parkinson's disease (PD), etc.
|
29696968 |
2018 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
The results show that tyrosinase, an enzyme important in melanin formation, is a principal autoantigen of autoimmune vitiligo.
|
7934446 |
1994 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Disturbance in the synthesis of tyrosinase might be one of the major causes of vitiligo.
|
22943168 |
2012 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
LHGDN |
Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity.
|
16272362 |
2005 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase and tyrosinase-related protein 1 (Tyr-Tyrp1) complex plays a critical role in the synthesis of melanin intermediates, which involves the production of reactive oxygen species (ROS) and contributes to the development of vitiligo.
|
25896941 |
2015 |
Vitiligo
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.
|
20410501 |
2010 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
<i>Psoralea corylifolia</i> L., (<i>P. corylifolia</i>), which is used for treating vitiligo in clinic, shows inhibitory and activating effects on tyrosinase, a rate-limiting enzyme of melanogenesis.
|
30400170 |
2018 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase is the key enzyme in the treatment of vitiligo.
|
30771911 |
2019 |
Vitiligo
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.
|
20410501 |
2010 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
These data confirm non-similarity to the host proteome as a factor that participates in shaping peptide immune reactivity and may be a first step towards designing tyrosinase antigenic peptides to be used for (i) direct neutralization of harmful melanocytes-attacking autoantibodies in vitiligo, or (ii) production of antibodies against tyrosinase-positive melanomas.
|
15946243 |
2005 |
Vitiligo
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.
|
22561518 |
2012 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
At least some of these residual CTLs in AAD(+)tyrosinase(+) mice were of high avidity and induced vitiligo upon adoptive transfer into AAD(+)tyrosinase(+) hosts.
|
10748239 |
2000 |
Vitiligo
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo.
|
11167683 |
2001 |
Vitiligo
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset.
|
21326295 |
2011 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
|
9328128 |
1997 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thus, the epitopes on tyrosinase recognized by vitiligo patient sera are heterogeneous and include a region with homology to two related proteins which may explain the cross-reactivity previously noted between these antigens.
|
10469315 |
1999 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase (TYR) is a key enzyme in melanin biosynthesis and its activity is an important biomarker for dermatological disorders, such as vitiligo, melanoma and actinic damages.
|
29126486 |
2017 |
Vitiligo
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The melanocyte percentages and tyrosinase mRNA presence in normal skin and vitiligo areas, before and after curettage and grafting, were compared.
|
16389417 |
2005 |
Vitiligo
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Therefore, defective 4a-hydroxytetrahydrobiopterin dehydratase in vitiligo influences not only the supply of L-tyrosine but also the transcription of the tyrosinase gene in melanocytes.
|
8204666 |
1994 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
We report that the tyrosinase autoantigen was immunorecognized with the same molecular pattern by sera from vitiligo and melanoma patients.
|
16272362 |
2005 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study has suggested the potential application of elastic cationic niosomes as an efficient topical delivery for tyrosinase gene in vitiligo therapy.
|
20213835 |
2010 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.
|
20083666 |
2010 |
Vitiligo
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.
|
27723757 |
2016 |
Vitiligo
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Theories including reactive oxygen species model, Nrf2-antioxidant response element (ARE) pathway, WNT pathway, tyrosinase activity, biochemical, molecular, and cellular alterations have been hypothesized to explain vitiligo pathogenesis.
|
29199612 |
2017 |
Vitiligo
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase (TYR), a key enzyme in biosynthesis of melanin, usually functions as a biomarker of severe skin diseases such as vitiligo and melanoma cancer.
|
29943981 |
2018 |